Hansoh Pharmaceutical Group Company Limited (FRA:3KY)
Germany · Delayed Price · Currency is EUR 4.080
+0.020 (0.49%)
At close: Jan 30, 2026
FRA:3KY Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 13,189 | 12,261 | 10,104 | 9,382 | 9,935 | 8,690 | |
Revenue Growth (YoY) | 9.02% | 21.35% | 7.69% | -5.56% | 14.32% | 0.09% |
Cost of Revenue | 1,208 | 1,117 | 1,033 | 870.19 | 870.39 | 803.41 |
Gross Profit | 11,981 | 11,144 | 9,071 | 8,512 | 9,065 | 7,887 |
Selling, General & Admin | 4,595 | 4,508 | 4,241 | 4,148 | 4,371 | 3,862 |
Research & Development | 2,946 | 2,702 | 2,097 | 1,693 | 1,797 | 1,252 |
Other Operating Expenses | -18.75 | 31.98 | 53.9 | 63.73 | 75.91 | - |
Operating Expenses | 7,522 | 7,242 | 6,392 | 5,905 | 6,244 | 5,114 |
Operating Income | 4,459 | 3,902 | 2,679 | 2,607 | 2,821 | 2,773 |
Interest Expense | -3.38 | -6.69 | -66.68 | -58.14 | -52.82 | -1.65 |
Interest & Investment Income | 1,117 | 1,046 | 1,020 | 331.52 | 253.85 | 163.92 |
Earnings From Equity Investments | - | - | -2.12 | -13.86 | - | - |
Currency Exchange Gain (Loss) | -8.66 | 21.43 | 4.57 | 44.56 | -9.31 | 63.37 |
Other Non Operating Income (Expenses) | 113.9 | 87.35 | 105.25 | 117.17 | 139.34 | 10.87 |
EBT Excluding Unusual Items | 5,678 | 5,050 | 3,741 | 3,029 | 3,152 | 3,009 |
Gain (Loss) on Sale of Investments | -25.27 | 61.27 | 158.22 | 67.58 | 144.49 | 88.91 |
Gain (Loss) on Sale of Assets | 7.13 | 5.72 | 2.1 | 11.24 | 3.94 | -0.04 |
Asset Writedown | -4.31 | -31.98 | - | - | - | - |
Other Unusual Items | - | - | -134.71 | -159.12 | - | - |
Pretax Income | 5,655 | 5,085 | 3,766 | 2,948 | 3,300 | 3,098 |
Income Tax Expense | 873.92 | 713.36 | 488.65 | 364.68 | 587.18 | 529.39 |
Net Income | 4,781 | 4,372 | 3,278 | 2,584 | 2,713 | 2,569 |
Net Income to Common | 4,781 | 4,372 | 3,278 | 2,584 | 2,713 | 2,569 |
Net Income Growth | 1.42% | 33.39% | 26.85% | -4.76% | 5.61% | 0.48% |
Shares Outstanding (Basic) | 5,936 | 5,930 | 5,925 | 5,916 | 5,921 | 5,876 |
Shares Outstanding (Diluted) | 5,955 | 5,950 | 6,020 | 5,929 | 5,998 | 5,878 |
Shares Change (YoY) | -1.10% | -1.16% | 1.52% | -1.14% | 2.04% | 7.31% |
EPS (Basic) | 0.81 | 0.74 | 0.55 | 0.44 | 0.46 | 0.44 |
EPS (Diluted) | 0.80 | 0.73 | 0.52 | 0.44 | 0.44 | 0.44 |
EPS Growth | 5.94% | 40.62% | 19.65% | -1.29% | 1.21% | -6.34% |
Free Cash Flow | 4,492 | 3,640 | 2,897 | 2,468 | 2,117 | 962.83 |
Free Cash Flow Per Share | 0.75 | 0.61 | 0.48 | 0.42 | 0.35 | 0.16 |
Dividend Per Share | 0.340 | 0.316 | 0.193 | 0.088 | 0.073 | 0.065 |
Dividend Growth | 8.08% | 63.53% | 118.47% | 20.84% | 12.44% | - |
Gross Margin | 90.84% | 90.89% | 89.78% | 90.72% | 91.24% | 90.75% |
Operating Margin | 33.81% | 31.83% | 26.52% | 27.79% | 28.39% | 31.91% |
Profit Margin | 36.25% | 35.66% | 32.44% | 27.54% | 27.31% | 29.56% |
Free Cash Flow Margin | 34.06% | 29.69% | 28.67% | 26.31% | 21.31% | 11.08% |
EBITDA | 4,812 | 4,278 | 3,025 | 2,932 | 3,084 | 2,989 |
EBITDA Margin | 36.49% | 34.89% | 29.94% | 31.25% | 31.04% | 34.40% |
D&A For EBITDA | 353.54 | 375.57 | 345.63 | 324.37 | 263.42 | 216.35 |
EBIT | 4,459 | 3,902 | 2,679 | 2,607 | 2,821 | 2,773 |
EBIT Margin | 33.81% | 31.83% | 26.52% | 27.79% | 28.39% | 31.91% |
Effective Tax Rate | 15.45% | 14.03% | 12.97% | 12.37% | 17.79% | 17.09% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.